Recordati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for…
Articles by Patricia Inácio, PhD
On average, people with Cushing’s syndrome wait 34 months before receiving a definite diagnosis, but waiting time largely depends…
A Phase 3 trial evaluating Corcept Therapeutics‘ relacorilant in treating the high blood pressure and poorer glucose tolerance in…
A European Medicines Agency (EMA) committee has recommended the approval of osilodrostat — to be marketed as…
Surgically removing both adrenal glands is a safe and effective way to control excessive cortisol levels in people with…
Positron emission tomography (PET) scans help identify neuroendocrine tumors causing ectopic Cushing’s syndrome in patients whose disease persisted…
Levels of adrenocorticotropic hormone (ACTH) in circulation after pituitary surgery may help predict which Cushing’s disease patients will…
Tumors in the thymus that produce too much of the adrenocorticotropic hormone (ACTH) may be the cause of ectopic Cushing’s…
The European Medicine Agency‘s Committee for Orphan Medicinal Products (COMP) has recommended that Corcept Therapeutics‘ relacorilant receive orphan…
Elevated cortisol levels in people with subclinical Cushing’s syndrome appear to increase their likelihood of metabolic disease — a group of…